View all newsletters
Receive our newsletter – data, insights and analysis delivered to you
  1. Uncategorised
April 1, 2020

Fujifilm commences Phase III trial of influenza drug Avigan for Covid-19

Fujifilm Toyama Chemical has started a Phase III clinical trial of its antiviral influenza drug Avigan (favipiravir) for the treatment of Covid-19 patients in Japan.

Avigan specifically blocks RNA polymerase associated with influenza viral replication.

The mechanism is expected to have an antiviral effect on SARS-CoV-2, the novel coronavirus that causes Covid-19.

Read the full article here

Related Companies

Topics in this article:
NEWSLETTER Sign up Tick the boxes of the newsletters you would like to receive. A weekly roundup of the latest news and analysis, sent every Friday. The pharmaceutical industry's most comprehensive news and information delivered every month.
I consent to GlobalData UK Limited collecting my details provided via this form in accordance with the Privacy Policy
SUBSCRIBED

THANK YOU